Prognostic relevance of immunohistology, tumor size and vascular space involvement in axillary node negative breast cancer

1998 ◽  
Vol 261 (3) ◽  
pp. 139-146 ◽  
Author(s):  
B. Lampe ◽  
P. Hantschmann ◽  
T. Dimpfl
Keyword(s):  
Breast Cancer ◽  
Tumor Size ◽  
Axillary Node ◽  
Node Negative ◽  
Prognostic Relevance ◽  
Vascular Space ◽  
Node Negative Breast Cancer

scholarly journals Tumor-Biological Factors Upa and PAI-1 as Stratification Criteria of a Multicenter Adjuvant Chemotherapy Trial in Node-Negative Breast Cancer

2000 ◽  
Vol 15 (1) ◽  
pp. 73-78 ◽  
Author(s):  
A. Prechtl ◽  
N. Harbeck ◽  
C. Thomssen ◽  
C. Meisner ◽  
M. Braun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Plasminogen Activator ◽  
Systemic Therapy ◽  
Axillary Node ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Node Negative Breast Cancer ◽  
Pai 1

In axillary node-negative primary breast cancer, 70% of the patients will be cured by locoregional treatment alone. Therefore, adjuvant systemic therapy is only needed for those 30% of node-negative patients who will relapse after primary therapy and eventually die of metastases. Traditional histomorphological and clinical factors do not provide sufficient information to allow accurate risk group assessment in order to identify node-negative patients who might benefit from adjuvant systemic therapy. In the last decade various groups have reported a strong and statistically independent prognostic impact of the serine protease uPA (urokinase-type plasminogen activator) and its inhibitor PAI-1 (plasminogen activator inhibitor type 1) in node-negative breast cancer patients. Based on these data, a prospective multicenter therapy trial in node-negative breast cancer patients was started in Germany in June 1993, supported by the German Research Association (DFG). Axillary node-negative breast cancer patients with high levels of either or both proteolytic factors in the tumor tissue were randomized to adjuvant CMF chemotherapy versus observation only. Recruitment was continued until the end of 1998, by which time 684 patients had been enrolled. Since then, patients have been followed up in order to assess the value of uPA and PAI-1 determination as an adequate selection criterion for adjuvant chemotherapy in node-negative breast cancer patients. This paper reports on the rationale and design of this prospective multicenter clinical trial, which may have an impact on future policies in prognosis-oriented treatment strategies.

Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer

1986 ◽  
Vol 7 (3) ◽  
pp. 161-169 ◽  
Author(s):  
Rosella Silvestrini ◽  
Maria Grazia Daidone ◽  
Giovanni Di Fronzo ◽  
Alberto Morabito ◽  
Pinuccia Valagussa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptors ◽  
Tumor Size ◽  
Labeling Index ◽  
Prognostic Implication ◽  
Node Negative ◽  
Node Negative Breast Cancer

Number of lymph nodes removed in sentinel lymph node-negative breast cancer patients is significantly related to patient age and tumor size

Cancer ◽  
2010 ◽  
Vol 116 (8) ◽  
pp. 1987-1991 ◽  
Author(s):  
Elisa Rush Port ◽  
Sujata Patil ◽  
Michelle Stempel ◽  
Monica Morrow ◽  
Hiram S. Cody
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Tumor Size ◽  
Breast Cancer Patients ◽  
Patient Age ◽  
Node Negative ◽  
Node Negative Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document